Castle Creek Arbitrage’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Castle Creek Arbitrage’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,000	Closed	-$505K	–	584
2022 Q4	$505K	Hold	50,000	–	–	0.04%	214
2022 Q3	$496K	Hold	50,000	–	–	0.03%	342
2022 Q2	$493K	Sell	50,000 -50,000	-50%	-$490K	0.03%	340
2022 Q1	$986K	Hold	100,000	–	–	0.05%	308
2021 Q4	$983K	Hold	100,000	–	–	0.05%	314
2021 Q3	$974K	Hold	100,000	–	–	0.06%	265
2021 Q2	$966K	Hold	100,000	–	–	0.05%	304
2021 Q1	$971K	Buy	+100,000	New	+$968K	0.06%	290

Castle Creek Arbitrage's BIOT Position: Q1 2023 in Review

Castle Creek Arbitrage sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 50,000 shares — an estimated $505K sold.

Castle Creek Arbitrage first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $986K in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Castle Creek Arbitrage reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Castle Creek Arbitrage sold 50,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $505K.
Castle Creek Arbitrage first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Castle Creek Arbitrage's Biotech Acquisition Company Class A Ordinary Shares position peaked at $986K in Q1 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Castle Creek Arbitrage's 13F filing for Q1 2023, filed 15 May 2023.